Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for reducing morbidity in patients with heart failure following a myocardial infarction, primarily in adult populations.

GNH USA supplies Inspra as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under regulated quality standards. Our supply chain ensures consistent availability and compliance with EU regulatory requirements, supporting healthcare providers in delivering evidence‑based cardiovascular therapy.

Eplerenone is an aldosterone antagonist used in cardiovascular disease management. Hypertension: lowers blood pressure by reducing sodium retention. Heart failure (post‑myocardial infarction): improves survival and reduces hospitalizations. Chronic heart failure with reduced ejection fraction: decreases cardiac remodeling and symptom burden.

Adverse reactions may occur with eplerenone therapy.

Common Side Effects: - Hyperkalemia - Dizziness - Headache - Diarrhea - Nausea - Fatigue

Serious or Rare Side Effects: - Severe hyperkalemia - Acute renal failure - Angioedema - Hepatic dysfunction - Marked hypotension - Severe allergic reactions

Before initiating therapy, consider the following precautions: - Monitor serum potassium: check baseline and periodic levels. - Assess renal function: evaluate creatinine clearance before and during treatment. - Avoid use in severe renal impairment: contraindicated when eGFR <30 mL/min/1.73 m². - Caution in patients with existing hyperkalemia: adjust dose or discontinue. - Use with care during pregnancy (Category B): discuss risks with a healthcare professional. - Store at ambient temperature: keep in the original pack, protect from moisture.

Eplerenone may interact with several medications.

Major Interactions (Avoid): - Potassium supplements or high‑potassium diets: increase risk of hyperkalemia. - ACE inhibitors or ARBs: additive potassium elevation. - NSAIDs: may impair renal function and raise potassium levels. - Cyclosporine: can markedly increase serum potassium.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may alter potassium balance. - Digoxin: potassium changes can affect digoxin toxicity. - Lithium: renal effects may increase lithium levels. - Rifampin: may reduce eplerenone plasma concentrations.